PE20151055A1 - Compuestos triciclicos para inhibir el canal cftr - Google Patents

Compuestos triciclicos para inhibir el canal cftr

Info

Publication number
PE20151055A1
PE20151055A1 PE2015001056A PE2015001056A PE20151055A1 PE 20151055 A1 PE20151055 A1 PE 20151055A1 PE 2015001056 A PE2015001056 A PE 2015001056A PE 2015001056 A PE2015001056 A PE 2015001056A PE 20151055 A1 PE20151055 A1 PE 20151055A1
Authority
PE
Peru
Prior art keywords
inhibit
tricyclic compounds
compounds
cftr channel
diona
Prior art date
Application number
PE2015001056A
Other languages
English (en)
Inventor
Mahbud Ahmed
Alexander Ashall-Kelly
Louisa Gueritz
Jeffrey Mckenna
Joseph Mckenna
Simon Mutton
Rakesh Parmar
Jon Shepherd
Paul Wright
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151055(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20151055A1 publication Critical patent/PE20151055A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS TRICICLICOS DE FORMULA (I) DONDE R1, R2, R3, R4, X, Z Y n SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: 1,3-DIMETIL-10-(5-METILFURAN-2-IL)-5-FENIL-7,8-DIHIDRO-1H-PIRIMIDO[4',5':3,4]PIRROLO[2,1-c][1,4]TIAZINA-2,4(3H,10H)-DIONA; 1,3-DIMETIL-10-(4-METILTIAZOL-2-IL)-5-FENIL-7,8-DIHIDRO-1H-PIRIMIDO[4',5':3,4]PIRROLO[2,1-c][1,4]TIAZINA-2,4(3H,10H)-DIONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA REGULADORA DE LA CONDUCTANCIA TRANSMENBRANA EN LA FIBROSIS QUISTICA (CFTR) SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL POLIQUISTICA Y DIARREA
PE2015001056A 2012-12-19 2013-12-17 Compuestos triciclicos para inhibir el canal cftr PE20151055A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739335P 2012-12-19 2012-12-19
US201361906141P 2013-11-19 2013-11-19

Publications (1)

Publication Number Publication Date
PE20151055A1 true PE20151055A1 (es) 2015-08-05

Family

ID=50030372

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001056A PE20151055A1 (es) 2012-12-19 2013-12-17 Compuestos triciclicos para inhibir el canal cftr

Country Status (25)

Country Link
US (2) US20140171417A1 (es)
EP (1) EP2935278B1 (es)
JP (1) JP6284546B2 (es)
KR (1) KR20150097660A (es)
CN (1) CN105143230B (es)
AP (1) AP2015008539A0 (es)
AR (1) AR094122A1 (es)
AU (1) AU2013365739A1 (es)
BR (1) BR112015014292A2 (es)
CA (1) CA2895660A1 (es)
CL (1) CL2015001730A1 (es)
CR (1) CR20150325A (es)
CU (1) CU20150066A7 (es)
EA (1) EA201591177A1 (es)
ES (1) ES2628369T3 (es)
HK (1) HK1209741A1 (es)
IL (1) IL239389A0 (es)
MX (1) MX2015007939A (es)
PE (1) PE20151055A1 (es)
PH (1) PH12015501386A1 (es)
SG (1) SG11201504594QA (es)
TN (1) TN2015000279A1 (es)
TW (1) TW201429974A (es)
UY (1) UY35211A (es)
WO (1) WO2014097148A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
BR112015014292A2 (pt) 2012-12-19 2017-07-11 Novartis Ag compostos tricíclicos para inibição do canal de cftr
US9303035B2 (en) 2012-12-19 2016-04-05 Novartis Ag Substituted pyrazino[1′,2′:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4′,5′:3,4]pyrrolo[2,1-c][1,4]oxazines and pyrimido[4′,5′:3,4]pyrrolo[1,2-d][1,4]oxazepines for inhibiting the CFTR channel
US10597496B2 (en) 2014-09-19 2020-03-24 Momentive Performance Materials Inc. Platinum (II) diene complexes for controlled siloxane crosslinking
CN106478558B (zh) * 2016-10-17 2019-03-29 天津雅奥科技发展有限公司 一种4-羟甲基-二氢-呋喃-2(3h)-酮的合成方法
EP4329815A1 (en) 2021-04-29 2024-03-06 Novartis AG Deubiquitinase-targeting chimeras and related methods
CN117654560B (zh) * 2023-12-01 2024-06-04 安徽泽升科技股份有限公司 一种通过氧化氨基连续化制备硝基化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE316089T1 (de) 1999-08-25 2006-02-15 Banyu Pharma Co Ltd Isoindolderivate
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
WO2009042270A2 (en) * 2007-07-05 2009-04-02 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
IN2012DN00719A (es) * 2009-08-10 2015-06-19 Univ California
WO2012166658A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
BR112015014292A2 (pt) 2012-12-19 2017-07-11 Novartis Ag compostos tricíclicos para inibição do canal de cftr
US9303035B2 (en) 2012-12-19 2016-04-05 Novartis Ag Substituted pyrazino[1′,2′:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4′,5′:3,4]pyrrolo[2,1-c][1,4]oxazines and pyrimido[4′,5′:3,4]pyrrolo[1,2-d][1,4]oxazepines for inhibiting the CFTR channel

Also Published As

Publication number Publication date
CL2015001730A1 (es) 2015-08-28
UY35211A (es) 2014-07-31
AP2015008539A0 (en) 2015-06-30
US20140171417A1 (en) 2014-06-19
IL239389A0 (en) 2015-07-30
WO2014097148A9 (en) 2015-02-19
CN105143230A (zh) 2015-12-09
SG11201504594QA (en) 2015-07-30
US20150336986A1 (en) 2015-11-26
PH12015501386A1 (en) 2015-09-02
CU20150066A7 (es) 2015-11-27
AU2013365739A1 (en) 2015-07-09
CN105143230B (zh) 2017-06-09
WO2014097148A1 (en) 2014-06-26
ES2628369T3 (es) 2017-08-02
KR20150097660A (ko) 2015-08-26
TN2015000279A1 (en) 2016-10-03
MX2015007939A (es) 2016-03-11
EP2935278B1 (en) 2017-03-15
HK1209741A1 (en) 2016-04-08
TW201429974A (zh) 2014-08-01
EA201591177A1 (ru) 2015-11-30
CA2895660A1 (en) 2014-06-26
JP6284546B2 (ja) 2018-02-28
JP2016509579A (ja) 2016-03-31
US9359381B2 (en) 2016-06-07
EP2935278A1 (en) 2015-10-28
CR20150325A (es) 2015-08-10
BR112015014292A2 (pt) 2017-07-11
AR094122A1 (es) 2015-07-08

Similar Documents

Publication Publication Date Title
PE20151055A1 (es) Compuestos triciclicos para inhibir el canal cftr
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CO6351786A2 (es) Inkibidores de la cinasa map p38
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
ECSP10010346A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
DOP2014000133A (es) Triazolopiridinas sustituidas
CR20110230A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
EA201791850A1 (ru) Борсодержащие малые молекулы
EA200970987A1 (ru) Трициклические азотсодержащие соединения в качестве антибактериальных агентов
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
ATE459622T1 (de) Tropanverbindungen
ECSP11011258A (es) Pirimidinas fusionadas
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
ECSP109945A (es) Nuevos herbicidas
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
PA8855001A1 (es) Monocarbamas
EA201200247A1 (ru) Новые азагетероциклические соединения

Legal Events

Date Code Title Description
FD Application declared void or lapsed